Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.

mBio · 2022 · PMC9765482 · PMID 36255239

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

While it is difficult to compare the findings from the ACTIV-3 study to the present analysis, given sample size limitations and differences in SARS-CoV-2 neutralization assays, both analyses indicate a clear trend toward benefit of monoclonal antibody therapy in patients lacking neutralizing antibody activity against SARS-CoV-2.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.